• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study shows health equity impact from Virta Health diabetes reversal platform

June 27, 2023 By Sean Whooley

Virta Health
[Image from Virta Health]
Virta Health announced that real-world data for its diabetes reversal platform demonstrated narrowing gaps in care.

The company shared its data at the American Diabetes Association’s 83rd Scientific Sessions. The research highlighted its impact on health equity. It demonstrated significant health improvement and medication reduction for members in the most and least disadvantaged U.S. neighborhoods.

Virta said diabetes disproportionately affects racial and ethnic minorities and those living in low-income areas. Additionally, those with financial hardships prove more likely to receive prescriptions for diabetes drugs that are older and harder to manage due to affordability and access. With complex regimens, these lower-income patients have a higher likelihood of hospitalization and severe diabetes complications.

According to Virta, its approach can narrow these gaps by helping members achieve better metabolic health. Meanwhile, they reduce or even eliminate the need for medications like insulin.

Virta — launched in 2017  — aims to reverse type 2 diabetes. It designed its technology platform to enable personalized remote care. Its offerings include physician supervision, health coaches, an app and biomarker tracking tools. It also offers a personalized nutrition plan for its patients in the hopes of reversing type 2 diabetes.

About the Virta Health data

The company studied a random sample of nearly 20,000 members grouped by Area Deprivation Index (ADI). Reflecting nationwide trends, those in the most disadvantaged areas had higher blood sugar levels at baseline. They often received prescriptions for more complex, lower-cost diabetes medications with a greater risk of hypoglycemia.

At one year, all Virta members saw significant health improvement and medication deprescription with the diabetes reversal approach. This proved effective regardless of socioeconomic conditions.

Across all groups, members achieved at least a 1.1% decrease in A1c. Insulin prescriptions fell by 38% or more and sulfonylureas fell by 77% at one year, Virta noted. Notably, the company said, more disadvantaged groups had medications reduced at greater rates.

Finally, across all groups, members saw 7% weight loss on average. The FDA considers 5% weight loss “clinically significant.”

“While there’s much discussion around improving health equity in diabetes, actual solutions are sparse,” said Dr. Michael Lenoir, president of the African American Wellness Project and former President of the National Medical Association. “That’s what makes these findings so exciting—they show definitively that Virta’s approach can narrow or even eliminate disparities in diabetes care.”

Filed Under: Clinical Trials, Diabetes, Technology Tagged With: ADA 2023, American Diabetes Association, Virta Health

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS